Naratriptan

Evidence Level: L5

Predicted Indications: 2

Naratriptan

Pharmacist Assessment Report

Naratriptan: Atrophoderma vermiculata

One-Sentence Summary

Naratriptan is a triptan originally used to treat acute migraine. However, there are no registered clinical trials and the 20 publications identified are mostly general migraine or triptan studies, so the prediction is supported mainly by similarity to the approved indication.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Atrophoderma vermiculata
TxGNN Prediction Score	0.9974
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Naratriptan is a selective 5-HT1B/1D receptor agonist approved for acute migraine. Currently, detailed mechanism of action data is not available in the data compiled for this report, but the class pharmacology of triptans is well established. It is believed to act on trigeminovascular activation, CGRP release and cranial vasodilation.

Migraine with brainstem aura is a subtype of migraine, so the underlying pathophysiology overlaps with the approved indication. This gives a plausible mechanistic link.

There are two caveats. First, none of the supplied literature studies brainstem aura specifically. Second, triptans have historically been used cautiously in this subtype (formerly called basilar-type migraine) because of theoretical vasoconstriction concerns. The high TxGNN score largely reflects similarity to the approved migraine indication, not independent evidence.

Two other predictions were also reviewed (atrophoderma vermiculata, 0.9974, and ulerythema ophryogenesis, 0.9947). Both have no clinical trials or literature and no plausible mechanistic link to 5-HT1B/1D agonism, so they are held at the model-prediction-only level (L5).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The publications below are general migraine or naratriptan studies. None addresses brainstem aura directly.

PMID	Year	Type	Journal	Key Findings
10972634	2000	RCT	Clinical Therapeutics	Randomized, double-blind crossover comparison of naratriptan and sumatriptan for headache recurrence in recurrence-prone migraine patients
10961768	2000	RCT	Cephalalgia	Naratriptan given during the prodrome to test prevention of migraine headache
11264684	2001	RCT (placebo-controlled)	Headache	Naratriptan 1 mg and 2.5 mg twice daily vs placebo as short-term prophylaxis of menstrually associated migraine
25600718	2015	Review	Headache	American Headache Society evidence assessment of acute migraine pharmacotherapies
25841032	2015	Cohort	Neurology	Sumatriptan was less effective in migraine with aura than without aura
14511276	2003	Review	Headache	Managing intractable migraine with naratriptan
21028917	2010	Review	Paediatric Drugs	Use of triptans for pediatric migraine
15926020	2005	Open-label pilot study	Neurological Sciences	Naratriptan as short-term prophylaxis of pure menstrual migraine
16268666	2005	Review	CNS Drugs	Triptans in the management of menstrual migraine
23877022	2014	Case report	Brain & Development	Naratriptan improved intractable migraine-like headaches in a patient with Sturge-Weber syndrome and prior cerebral infarction

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 152736	Naratrex 2.5 Tablet (Sun Pharmaceutical Industries Ltd)	Strip of 2 tablets (oral)	Not stated in the data compiled

Safety Considerations

Contraindications (from knowledge-graph drug-disease links, not label text): hypertension, liver failure, diabetes mellitus and diabetic ketoacidosis, coronary artery disease, myocardial infarction and myocardial ischemia, Prinzmetal angina, stroke and cerebrovascular disorders, cerebral infarction, transient ischemic attack, vertebrobasilar insufficiency, peripheral vascular and arterial disease, obesity, hemoglobinopathy, and familial or sporadic hemiplegic migraine.
Relevance to the predicted indication: vertebrobasilar insufficiency and hemiplegic migraine appear on the list. They are closely related to brainstem aura, so safety in this subtype needs explicit evaluation.
Drug Interactions: 39 interactions were identified. Major-level interactions include:
- Serotonergic and related agents: lorcaserin, fenfluramine, dexfenfluramine, sibutramine, methylene blue
- 5-HT3 antagonists: ondansetron, granisetron, dolasetron, palonosetron
Moderate-level interactions include morphine (including liposomal). Several others, such as omeprazole, pantoprazole, lansoprazole, clarithromycin, bupropion and prednisone, are of unknown severity.

Please also refer to the package insert, as label warnings were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is biologically plausible because brainstem aura is a migraine subtype. However, there are no clinical trials, no literature specific to brainstem aura, and a theoretical vascular safety concern in this very subtype. The high model score mainly reflects similarity to the approved indication. The evidence supports treating this as a research question rather than a development decision.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian label (a blocking gap for safety screening)
Detailed mechanism of action data
Subtype-specific evidence, such as case series, registries or controlled studies of triptans in brainstem aura
A formal cerebrovascular and cardiovascular safety assessment for this population
The approved indication text for the Indian registration, to confirm the original-indication baseline
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.